PNB 001 - PhageNova Bio
Alternative Names: PNB 001-PhageNova BioLatest Information Update: 21 Jul 2021
Price :
$50 *
At a glance
- Originator PhageNova Bio
- Class Antineoplastics; Bacteriophages; Gene therapies; Immunotherapies
- Mechanism of Action Gene transference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Solid tumours
Most Recent Events
- 14 Jul 2021 Preclinical trials in Solid tumours in USA (Parenteral) (PhageNova Bio pipeline, July 2021)
- 14 Jul 2021 PhageNova Bio announces intention to submit IND to US FDA for Solid tumours (PhageNova Bio pipeline, July 2021)
- 14 Jul 2021 PhageNova Bio plans a first in-human, dose escalating phase I trial for Solid tumours in 2022 (PhageNova Bio pipeline, July 2021)